Analysis
McKesson management has consistently maintained that the net financial impact of U.S. tariffs introduced since April 2025 is not material to its adjusted earnings guidance. The company’s primary mitigation strategy is a pass-through model where increased input costs from import duties are passed along to customers, including pharmacies, hospitals, and patients. While this approach protects McKesson's margins, management has acknowledged that it results in higher costs for patients in certain cases.
The company employs a nimble sourcing strategy to further mitigate tariff risks. Because McKesson does not own manufacturing plants or fixed capital in the affected countries, it can shift sourcing to more advantageous locations as trade policies evolve. During the FY2026 guidance cycle in early 2025, the company stated that its outlook already factored in the known tariff landscape and that exposure to markets like Mexico and Canada remained minimal.
Despite these mitigations, the tariff environment reached a point of significant escalation in April 2026 with the signing of a Section 232 Pharmaceutical Proclamation. This order imposes a 100% tariff on patented pharmaceuticals and active pharmaceutical ingredients (APIs), effective July 31, 2026. While McKesson’s fee-for-service model with manufacturers often provides a fixed fee for distribution that is independent of drug price fluctuations, the 100% tariff represents a structural reset for the industry that could impact broader utilization and demand.
In the Medical-Surgical Solutions segment, which McKesson is in the process of separating into an independent company, tariffs have had a more direct impact on product costs. Management previously noted that while these costs are passed through, they contribute to the complex operating environment for medical supplies. As of the most recent quarterly reports, McKesson reaffirmed its long-term growth targets, indicating that the cumulative impact of reciprocal and 'Liberation Day' tariffs remains navigable within its existing financial framework.
Sources
if there are tariffs that impact some of the products that we have, in some cases, we'll certainly pass those on to our customers. Unfortunately, it'll be a higher cost to patients in some cases.
We do not anticipate this is going to have a material impact on our fiscal 2026 guidance. It's our understanding of the tariff situation today.
As to your question on the tariffs as it relates to the pharmaceutical industry, it's been obviously a little bit volatile, and I would say we're still in a bit of an uncertain time where this all settles down.